申请人:Janssen Pharmaceutica NV
公开号:US20170320894A1
公开(公告)日:2017-11-09
The present invention concerns the compounds of formula
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
Z represents NH; Y represents —C
3-9
alkyl-, —C
1-5
alkyl-NR
13
—C
1-5
alkyl-, —C
1-5
alkyl-NR
14
—CO—C
1-5
alkyl-, —C
1-2
alkyl-NR
21
—H
2
—CO—NH—C
1-3
alkyl- or —C
1-2
alkyl-NR
23
—CO—CR
16
R
17
—NH—;
X
1
represents O or —O—C
1-2
alkyl-; X
2
represents a direct bond, C
1-2
alkyl, —CO—C
1-2
alkyl or NR
12
—C
1-2
alkyl;
R
1
represents hydrogen or halo; R
2
represents halo, acetylene or Het
1
R
3
represents hydrogen or cyano; R
4
represents Ar
4
—C
1-4
alkyloxy-, C
1-4
alkyloxy- or C
1-4
alkyloxy substituted with one or where possible two or more substituents selected from Het
2
, NR
7
R
8
, hydroxy and C
1-4
alkyloxy-C
1-4
alkyloxy-;
R
7
represents hydrogen or C
1-4
alkyl; R
8
represents C
1-4
alkyl substituted with NR
25
R
26
or C
1-4
alkylsulfonyl;
R
12
represents hydrogen or C
1-4
alkyl-; R
13
represents Ar
6
-sulfonyl or C
1-6
alkyloxycarbonyl optionally substituted with phenyl;
R
16
and R
17
represents hydrogen, C
1-4
alkyl or R
16
and R
17
taken together with the carbon atom to which they are attached from a C
3-6
cycloalkyl;
R
23
represents C
1-4
alkyl and R
23
represents hydrogen when R
16
and R
17
taken together with the carbon atom to which they are attached from a C
3-6
cycloalkyl;
R
25
, R
26
, R
27
and R
28
each independently represent hydrogen or C
1-4
alkylcarbonyl;
Het
1
represents 2-bora-1,3-dioxolanyl; Het
2
represents piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl or 1,1-dioxothiomorpholinyl wherein said Het
2
is optionally substituted with C
1-4
alkyloxycarbonyl or NR
27
R
28
—C
1-4
alkyl;
Ar
4
and Ar
5
represents phenyl; Ar
6
represents phenyl optionally substituted with nitro.